4-苯并噻唑 | 7405-23-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 4-苯并噻唑
• 中文别名: 4-羟基-苯并噻唑
• 英文名称: 4-hydroxybenzothiazole
• 英文别名: benzo[d]thiazol-4-ol；4-Hydroxy-benzthiazol；4-Hydroxy-benzothiazol；4-Benzothiazolol；1,3-benzothiazol-4-ol
• CAS: 7405-23-4
• 化学式: C₇H₅NOS
• mdl: MFCD11046398
• 分子量: 151.189
• InChiKey: NZFKDDMHHUEVPI-UHFFFAOYSA-N

物化性质

• 熔点：
  143℃
• 沸点：
  312℃
• 密度：
  1.444
• 闪点：
  142℃

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934200090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Benzothiazolol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Benzothiazolol
CAS number: 7405-23-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5NOS
Molecular weight: 151.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-苯并噻唑 在 吡啶 、 4-二甲氨基吡啶 、 sodium hydride 、 potassium carbonate 、 一水合肼 、 tin(ll) chloride 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 2-amino-N-[3-(1,3-benzothiazol-4-yloxymethyl)-2,4-dichlorophenyl]-N-methylacetamide
  参考文献：
  名称：

  O系列新的O-取代的8-喹啉和4-苯并噻唑类作为缓激肽B2受体的有效拮抗剂。

  摘要：

  描述了新型O-取代的8-喹啉和4-苯并噻唑作为高效非肽缓激肽B2受体拮抗剂的合成和SAR研究。该系列拮抗剂的几个成员有效抑制了BK诱导的不同分离器官制剂的血管收缩。

  DOI：

  10.1016/s0960-894x(98)00736-7
• 作为产物：
  描述：

  2-氨基-4-甲氧基苯并噻唑 在 PPA 、 三溴化硼 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 4-苯并噻唑
  参考文献：
  名称：

  [EN] 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPHINEPHRINE REUPTAKE
  [FR] COMPOSES PHARMACEUTIQUES

  摘要：

  提供一种具有以下结构的化合物（I）：其中A从-O-和-S-中选择；X从C2-C8烷基，C2-C8烯基，C3-C8环烷基和C4-C8环烷基烷基中选择，每种基团可能分别被选自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S(O)n-（其中n为0，1或2），-CF3，-CN和-CONH2的最多3个取代基所取代；Y从苯基，萘基，二氢苯并噻吩基，苯并噻唑基，苯并异噻唑基，喹啉基，异喹啉基，萘啉基，噻吩吡啉基，茚基，1,3-苯并二氧杂环戊基，苯并噻吩基，吲哚基和苯并呋喃基中选择，每种基团可能分别被选自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S(O)n-（其中n为0，1或2），硝基，乙酰基，-CF3，-SCF3和氰基的最多4个或在可能的情况下5个取代基所取代；当Y为吲哚基时，它可以被选自C1-C4烷基的N-取代基取代或进一步取代；Z从H，OR3或F中选择，其中R3从H，C1-C6烷基和苯基C1-C6烷基中选择；R1和R2分别独立地为H或C1-C4烷基；但是，当Z为H时，Y可能不是可选择地取代的苯基或可选择地取代的萘基。

  公开号：

  WO2004043904A1

文献信息

• [EN] 3-ARYLOXY/ THIO-2, 3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE<br/>[FR] 3-ARYLOXY/THIO-2, 3-SUBSTITUE PROPANAMINES ET LEUR UTILISATION POUR INHIBER LE RECAPTAGE DE LA SEROTONINE ET DE LA NOREPINEPHRINE
  申请人：LILLY CO ELI

  公开号：WO2004043903A1

  公开（公告）日：2004-05-27

  There is provided a compound of formula (I) wherein A is selected from -O- and -S-; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C1-C4 alkyl, and C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C1-C4 alkyl; Z is selected from OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl C1-C6 alkyl; R1 and R2 are each independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereofwith the proviso that when Y is optionally substituted phenyl or optionally substituted 1,3-benzodioxolyl and Z is OR3 and X is optionally substituted phenyl then A is -S-.

  提供一种化合物，其化学式为（I），其中A从-O-和-S-中选择；X从苯基选项地取代，每个取代基可独立地从卤素、C1-C4烷基和C1-C4烷氧基中选择最多5个取代基，噻吩基选项地取代，每个取代基可独立地从卤素和C1-C4烷基中选择最多3个取代基，以及C2-C8烷基、C2-C8烯基、C3-C8环烷基和C4-C8环烷基烷基，每个基可选地取代，每个取代基可独立地从卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n-（其中n为0、1或2）、-CF3、-CN和-CONH2中选择；Y从苯基、萘基、二氢苯并噻吩基、苯并噻唑基、苯并异噻唑基、喹啉基、异喹啉基、萘啉基、噻吩吡啉基、茚基、1,3-苯并二氧杂环戊基、苯并噻吩基、吲哚基和苯并呋喃基中选择，每个基可选地取代，最多可独立地从卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n-（其中n为0、1或2）、硝基、乙酰基、-CF3、-SCF3和氰基中选择最多4个或在可能的情况下最多5个取代基；当Y为吲哚基时，它可以被取代或进一步被N-取代基取代，N-取代基从C1-C4烷基中选择；Z从OR3或F中选择，其中R3从H、C1-C6烷基和苯基C1-C6烷基中选择；R1和R2各自独立地为H或C1-C4烷基；以及其药学上可接受的盐，但有一个条件，即当Y为可选地取代的苯基或可选地取代的1,3-苯并二氧杂环戊基，Z为OR3且X为可选地取代的苯基时，A为-S-。
• [EN] 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS D'AZÉTIDINE OU DE CYCLOBUTANE 1,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROSTAGLANDINE D SYNTHASE HÉMATOPOÏÉTIQUE (H-PGDS)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018069863A1

  公开（公告）日：2018-04-19

  A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式（I）的化合物，其中R、R1、R2、R3、Y、Y1、a、X和Z的定义如本文所述。本发明的化合物是造血前列腺素D合成酶（H-PGDS）的抑制剂，可用于治疗杜兴氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制H-PGDS活性和治疗相关疾病的方法。
• Characterization of Aminobenzylphenols as Protein Disulfide Isomerase Inhibitors in Glioblastoma Cell Lines
  作者：Andrea Shergalis、Ding Xue、Fatma Z. Gharbia、Hannah Driks、Binita Shrestha、Amina Tanweer、Kirin Cromer、Mats Ljungman、Nouri Neamati

  DOI：10.1021/acs.jmedchem.0c00728

  日期：2020.9.24

  Disulfide bond formation is a critical post-translational modification of newly synthesized polypeptides in the oxidizing environment of the endoplasmic reticulum and is mediated by protein disulfide isomerase (PDIA1). In this study, we report a series of α-aminobenzylphenol analogues as potent PDI inhibitors. The lead compound, AS15, is a covalent nanomolar inhibitor of PDI, and the combination of

  二硫键形成是在内质网氧化环境中新合成多肽的关键翻译后修饰，由蛋白质二硫键异构酶 (PDIA1) 介导。在这项研究中，我们报告了一系列 α-氨基苄基苯酚类似物作为有效的 PDI 抑制剂。先导化合物AS15是一种共价纳摩尔 PDI 抑制剂，AS15类似物与谷胱甘肽合成抑制剂丁硫氨酸亚砜亚胺 (BSO) 的组合可协同抑制细胞生长。使用新生的 RNA 测序，我们展示了一个AS15类似物触发胶质母细胞瘤细胞中未折叠的蛋白质反应。BODIPY 标记的类似物与包括 PDIA1 在内的蛋白质结合，表明这些化合物具有细胞渗透性并达到预期目标。总之，这些发现证明了一系列与 PDI 共价结合的高效活性小分子的广泛生化特征。
• [EN] 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPHINEPHRINE REUPTAKE<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2004043904A1

  公开（公告）日：2004-05-27

  There is provided a compound of formula (I) wherein A is selected from -O- and -S-; X is selected from C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C1-C4 alkyl; Z is selected from H, OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl C1-C6 alkyl; R1 and R2 are each independently H or C1-C4 alkyl; with the proviso that, when Z is H, then Y may not be optionally substituted phenyl or optionally substituted naphthyl.

  提供一种具有以下结构的化合物（I）：其中A从-O-和-S-中选择；X从C2-C8烷基，C2-C8烯基，C3-C8环烷基和C4-C8环烷基烷基中选择，每种基团可能分别被选自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S(O)n-（其中n为0，1或2），-CF3，-CN和-CONH2的最多3个取代基所取代；Y从苯基，萘基，二氢苯并噻吩基，苯并噻唑基，苯并异噻唑基，喹啉基，异喹啉基，萘啉基，噻吩吡啉基，茚基，1,3-苯并二氧杂环戊基，苯并噻吩基，吲哚基和苯并呋喃基中选择，每种基团可能分别被选自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S(O)n-（其中n为0，1或2），硝基，乙酰基，-CF3，-SCF3和氰基的最多4个或在可能的情况下5个取代基所取代；当Y为吲哚基时，它可以被选自C1-C4烷基的N-取代基取代或进一步取代；Z从H，OR3或F中选择，其中R3从H，C1-C6烷基和苯基C1-C6烷基中选择；R1和R2分别独立地为H或C1-C4烷基；但是，当Z为H时，Y可能不是可选择地取代的苯基或可选择地取代的萘基。
• [EN] PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS<br/>[FR] DERIVES DE PROPANAMINE UTILISES EN TANT QU'INIHIBITEURS DU RECAPTAGE DE LA SEROTONINE ET DE LA NOREPINEPHRINE
  申请人：LILLY CO ELI

  公开号：WO2004043931A1

  公开（公告）日：2004-05-27

  There is provided a heretoaryloxy/thio 3-substituted propanamine compound of formula (I) wherein A is selected from -O- and -S-; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C1-C4 alkyl, and C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, and thienopyridyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; Z is selected from H, OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl C1-C6 alkyl; R1 and R2 are each independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereof.

  提供了一种公式（I）的醚/硫代3-取代丙胺化合物，其中A选自-O-和-S-；X选自苯基，可选地取代为最多5个取代基，每个取代基独立选自卤素、C1-C4烷基和C1-C4烷氧基，噻吩基，可选地取代为最多3个取代基，每个取代基独立选自卤素和C1-C4烷基，以及C2-C8烷基，C2-C8烯基，C3-C8环烷基和C4-C8环烷基烷基，每个基可选地取代为最多3个取代基，每个取代基独立选自卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n-其中n为0、1或2、-CF3、-CN和-CONH2；Y选自二氢苯并噻吩基，苯并噻唑基，苯并异噻唑基，喹啉基，异喹啉基，萘啉基和噻吩吡啉基，每个基可选地取代为最多4个或在可能的情况下，最多5个取代基，每个取代基独立选自卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n-其中n为0、1或2、硝基、乙酰基、-CF3、-SCF3和氰基；Z选自H、OR3或F，其中R3选自H、C1-C6烷基和苯基C1-C6烷基；R1和R2各自独立地为H或C1-C4烷基；以及其药学上可接受的盐。